ACADIA Pharmaceuticals Inc. (ACAD) Q4 FY25 Earnings Call

Commercial momentum supports 2026 growth, but EU regulatory setbacks and pivotal pipeline risk remain material [52][38].

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-01
Length63 minutes
EPS$0.16
EPS consensus$0.12
Revenue$284.0M
Revenue consensus$292.5M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26 · Q1 FY26

All ACAD earnings · Back to ACAD overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.